Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Certara Inc (CERT)

Certara Inc (CERT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,541,763
  • Shares Outstanding, K 159,273
  • Annual Sales, $ 385,150 K
  • Annual Income, $ -12,050 K
  • EBIT $ 82 M
  • EBITDA $ 151 M
  • 60-Month Beta 1.46
  • Price/Sales 3.83
  • Price/Cash Flow 12.88
  • Price/Book 1.40

Options Overview Details

View History
  • Implied Volatility 254.45% (+20.51%)
  • Historical Volatility 85.52%
  • IV Percentile 95%
  • IV Rank 68.95%
  • IV High 347.14% on 11/28/25
  • IV Low 48.60% on 01/21/25
  • Expected Move (DTE 14) 1.06 (11.10%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 17
  • Volume Avg (30-Day) 64
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 1,478
  • Open Int (30-Day) 2,686
  • Expected Range 8.51 to 10.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.07
  • Number of Estimates 3
  • High Estimate 0.09
  • Low Estimate 0.06
  • Prior Year 0.12
  • Growth Rate Est. (year over year) -41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.02 +19.25%
on 11/20/25
11.71 -18.27%
on 11/06/25
-1.98 (-17.14%)
since 11/04/25
3-Month
8.02 +19.25%
on 11/20/25
13.88 -31.05%
on 10/03/25
-1.01 (-9.55%)
since 09/04/25
52-Week
8.02 +19.25%
on 11/20/25
15.69 -39.01%
on 02/14/25
-1.31 (-12.04%)
since 12/04/24

Most Recent Stories

More News
AI Spending in Healthcare and Wellness Triples as Personalized Wellness Platforms Scale

Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – Healthcare's artificial intelligence transformation is accelerating at unprecedented speed, with AI spending hitting...

OPRX : 14.65 (+2.30%)
CTSH : 80.20 (+1.21%)
CERT : 9.57 (-1.14%)
OABI : 1.9700 (+4.79%)
ALEN-U.CN : 1.3400 (unch)
AI Wellness Market Surges as Personalized Health Platforms Capture Investment Flow

Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – AI-powered wellness platforms are commercializing rapidly as major technology companies launch personalized health...

ZBH : 93.16 (+0.06%)
CAI : 28.32 (+3.96%)
CERT : 9.57 (-1.14%)
ACN : 269.34 (-1.29%)
ALEN-U.CN : 1.3400 (unch)
Certara Reports Third Quarter 2025 Financial Results

RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year...

CERT : 9.57 (-1.14%)
Certara Automates Scientific Workflows with Phoenix® Cloud

RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module...

CERT : 9.57 (-1.14%)
Certara to Participate in Upcoming Investor Conferences

RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following...

CERT : 9.57 (-1.14%)
Certara Expands Biosimulation Market with AI-Driven QSP Platform

RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative...

CERT : 9.57 (-1.14%)
Certara Scientists are Among the Topmost Cited Biopharma Researchers

RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research. With...

CERT : 9.57 (-1.14%)
Morgan Stanley Remains a Hold on Certara (CERT)

In a report released today, Craig Hettenbach from Morgan Stanley maintained a Hold rating on Certara, with a price target of $16.00. The company’s shares closed yesterday at $12.25.Elevate Your Investing...

CERT : 9.57 (-1.14%)
Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025

RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after...

CERT : 9.57 (-1.14%)
Certara (CERT) Gets a Buy from Craig-Hallum

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Certara. The company’s shares opened today at $13.52.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

CERT : 9.57 (-1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Certara Inc. provides medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Certara Inc. is based in NJ, United States.

See More

Key Turning Points

3rd Resistance Point 10.02
2nd Resistance Point 9.87
1st Resistance Point 9.72
Last Price 9.57
1st Support Level 9.42
2nd Support Level 9.27
3rd Support Level 9.12

See More

52-Week High 15.69
Fibonacci 61.8% 12.76
Fibonacci 50% 11.86
Fibonacci 38.2% 10.95
Last Price 9.57
52-Week Low 8.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar